Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) have a high incidence and mortality rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is required for further progress. Immunotherapy is a considerable therapeutic strategy for HNSCC due to its potential to produce a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.941750/full |
| _version_ | 1798035963036827648 |
|---|---|
| author | Chenhang Yu Qiang Li Yu Zhang Zhi-Fa Wen Heng Dong Yongbin Mou |
| author_facet | Chenhang Yu Qiang Li Yu Zhang Zhi-Fa Wen Heng Dong Yongbin Mou |
| author_sort | Chenhang Yu |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) have a high incidence and mortality rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is required for further progress. Immunotherapy is a considerable therapeutic strategy for HNSCC due to its potential to produce a broad and long-lasting antitumor response. However, immune escape, which involves mechanisms including dyregulation of cytokines, perturbation of immune checkpoints, and recruitment of inhibitory cell populations, limit the efficacy of immunotherapy. Currently, multiple immunotherapy strategies for HNSCC have been exploited, including immune checkpoint inhibitors, costimulatory agonists, antigenic vaccines, oncolytic virus therapy, adoptive T cell transfer (ACT), and epidermal growth factor receptor (EGFR)-targeted therapy. Each of these strategies has unique advantages, and the appropriate application of these immunotherapies in HNSCC treatment has significant value for patients. Therefore, this review comprehensively summarizes the mechanisms of immune escape and the characteristics of different immunotherapy strategies in HNSCC to provide a foundation and consideration for the clinical treatment of HNSCC. |
| first_indexed | 2024-04-11T21:05:52Z |
| format | Article |
| id | doaj.art-6da17b577fc1480f8325e6b771924937 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-04-11T21:05:52Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-6da17b577fc1480f8325e6b7719249372022-12-22T04:03:16ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-08-011010.3389/fcell.2022.941750941750Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinomaChenhang Yu0Qiang Li1Yu Zhang2Zhi-Fa Wen3Heng Dong4Yongbin Mou5Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, ChinaNanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, ChinaNanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, ChinaDepartment of Clinical Laboratory, Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Clinical Laboratory, Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Clinical Laboratory, Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, ChinaHead and neck squamous cell carcinoma (HNSCC) have a high incidence and mortality rate, and investigating the pathogenesis and potential therapeutic strategies of HNSCC is required for further progress. Immunotherapy is a considerable therapeutic strategy for HNSCC due to its potential to produce a broad and long-lasting antitumor response. However, immune escape, which involves mechanisms including dyregulation of cytokines, perturbation of immune checkpoints, and recruitment of inhibitory cell populations, limit the efficacy of immunotherapy. Currently, multiple immunotherapy strategies for HNSCC have been exploited, including immune checkpoint inhibitors, costimulatory agonists, antigenic vaccines, oncolytic virus therapy, adoptive T cell transfer (ACT), and epidermal growth factor receptor (EGFR)-targeted therapy. Each of these strategies has unique advantages, and the appropriate application of these immunotherapies in HNSCC treatment has significant value for patients. Therefore, this review comprehensively summarizes the mechanisms of immune escape and the characteristics of different immunotherapy strategies in HNSCC to provide a foundation and consideration for the clinical treatment of HNSCC.https://www.frontiersin.org/articles/10.3389/fcell.2022.941750/fullimmunotherapyhead and neck cancersquamous cell carcinomaimmune escapeoral squamous cell carcinoma |
| spellingShingle | Chenhang Yu Qiang Li Yu Zhang Zhi-Fa Wen Heng Dong Yongbin Mou Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma Frontiers in Cell and Developmental Biology immunotherapy head and neck cancer squamous cell carcinoma immune escape oral squamous cell carcinoma |
| title | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| title_full | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| title_fullStr | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| title_full_unstemmed | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| title_short | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| title_sort | current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma |
| topic | immunotherapy head and neck cancer squamous cell carcinoma immune escape oral squamous cell carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2022.941750/full |
| work_keys_str_mv | AT chenhangyu currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma AT qiangli currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma AT yuzhang currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma AT zhifawen currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma AT hengdong currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma AT yongbinmou currentstatusandperspectiveoftumorimmunotherapyforheadandnecksquamouscellcarcinoma |